Research Topics
| Jeffery M WeinbergSummaryAffiliation: Columbia University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Topical therapy for actinic keratoses: current and evolving therapiesJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
Rev Recent Clin Trials 1:53-60. 2006..Several topical treatment options have been shown to offer some significant benefit in the alleviation of these lesions. The therapies include 5-fluorouracil, imiquimod, diclofenac, colchicine and retinoids...
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefaceptJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
J Drugs Dermatol 1:303-10. 2002..The mechanism of each drug will be reviewed, as well as the most recent efficacy and safety data...
Atopic dermatitis: a new treatment paradigm using pimecrolimusJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
J Drugs Dermatol 2:131-40. 2003..We then discuss various aspects of pimecrolimus, including pharmacologic properties, toxicology, short- and long-term studies, and safety and adverse events. Finally, we propose a new steroid-sparing treatment strategy for AD...
Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefaceptWilliam D Tutrone
St Luke s Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
IDrugs 7:45-9. 2004....
Cutaneous infections in the elderly: diagnosis and managementJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
Dermatol Ther 16:195-205. 2003..With limited treatment options, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives, including linezolid and quinupristin/dalfopristin...
Successful treatment of recalcitrant palmoplantar psoriasis with etanerceptJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
Cutis 72:396-8. 2003..We report a case of successful treatment of recalcitrant palmoplantar psoriasis with etanercept in a 59-year-old woman unresponsive to other treatment modalities...
An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasisJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Clin Ther 25:2487-505. 2003..One of the major focuses in psoriasis research has been the development of biologic therapies that provide selective, immunologically directed intervention with fewer adverse effects than traditional therapies...
Acquired dermal melanocytosisJeffrey M Weinberg
Department of Dermatology, St Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
Am J Clin Dermatol 8:59-60. 2007
Skin infections in the elderlyJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Dermatol Clin 22:51-61. 2004..With treatment options limited, it has become critical to identify antibiotics with novel mechanisms of activity. Several new drugs have emerged as possible therapeutic alternatives, including linezolid and quinupristin-dalfopristin...
Formulary review of therapeutic alternatives for atopic dermatitis: focus on pimecrolimusJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
J Manag Care Pharm 11:56-64. 2005..Pimecrolimus is indicated for mild-to-moderate AD. The objective of this article is to review the key characteristics that differentiate pimecrolimus from steroids and tacrolimus in the treatment of AD...
Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefaceptJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
J Drugs Dermatol 4:544-55. 2005....
The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgarisJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
J Drugs Dermatol 5:344-9. 2006..Clinical studies demonstrating the efficacy and safety of benzoyl peroxide in hydrophase base will be reviewed...
Treatment of interdigital tinea pedis: once-daily therapy with sertaconazole nitrateJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
J Drugs Dermatol 10:1135-40. 2011..8 percent were free of pruritus; no relapses had occurred. These encouraging findings suggest that sertaconazole nitrate may be useful in a once-daily regimen and also may result in better patient adherence to therapy...
Herpes zoster: epidemiology, natural history, and common complicationsJeffrey M Weinberg
Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center, and Columbia University College of Physicians and Surgeons, New York, New York 10025, USA
J Am Acad Dermatol 57:S130-5. 2007..The zoster vaccine may help prevent the onset of herpes zoster in the target population of those age 60 years and older. This summary reviews the epidemiology, pathogenesis, natural history, and common symptoms of zoster disease...
Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureusJeffrey M Weinberg
Clinical Research Center, Department of Dermatology, St Luke s Roosevelt Hospital Center, NewYork, NY 10025, USA
J Drugs Dermatol 9:1198-204. 2010..aureus and Streptococcus pyogenes and may play an important role in limiting the development of resistance against systemic agents...
Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanerceptJeffrey M Weinberg
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
Cutis 71:25-9. 2003..The structure and mechanism of each drug will be reviewed, as well as the most recent clinical experience and safety data. The first article of this review will focus on the therapies that inhibit tumor necrosis factor alpha (TNF-alpha)...
Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefaceptJeffrey M Weinberg
Department of Dermatology St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
Cutis 71:41-5. 2003..The first article of this 2-part update reviewed the tumor necrosis factor (TNF) inhibitors, infliximab and etanercept. In this article, we will review 2 therapies that target the T cell, efalizumab and alefacept...
Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanerceptBoback Berookhim
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Ave, Suite 11D, New York, NY 10025, USA
Cutis 74:245-7. 2004..To our knowledge, this is the first report of its efficacy in the treatment of PV...
EtanerceptErin Ducharme
St Luke s Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Expert Opin Biol Ther 8:491-502. 2008..Etanercept is a soluble fusion protein that binds TNF-alpha, rendering the molecule inactive and making etanercept an effective, targeted therapeutic option for many TNF-mediated inflammatory diseases...
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimusRitu Saini
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, 1090 Amsterdam Avenue, New York, NY 10025, USA
Curr Pharm Des 11:273-80. 2005..Clinical data for these agents, including the most recent phase II and/or III study results, will be discussed, as well as the most recent safety data...
Innovative uses of tumor necrosis factor alpha inhibitorsJoni Mazza
Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
Dermatol Clin 28:559-75. 2010..Numerous case reports and case series have been published in recent years reporting the off-label uses of these drugs in various inflammatory skin diseases. This review summarizes the most recent reports on 20 such conditions...
Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virusMaryann Mikhail
Department of Dermatology, St Luke's-Roosevelt Hospital Center, 1090 Amsterdam Ave, Ste 11B, New York, NY 10025, USA
Arch Dermatol 144:453-6. 2008
Levamisole in dermatology : a reviewNoah Scheinfeld
Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Centers, New York, New York 10025, USA
Am J Clin Dermatol 5:97-104. 2004..It can rarely cause agranulocytosis. More studies need to be undertaken to study the full potential of levamisole in dermatologic diseases...
Topical therapy in the treatment of actinic keratosis and basal cell carcinomaMarissa D Newman
Department of Dermatology, UMDNJ Robert Wood Johnson Medical School, Newark, USA
Cutis 79:18-28. 2007..The topical therapies include 5-fluorouracil (5-FU), diclofenac sodium, colchicine, retinoids, and imiquimod. Topical treatment of basal cell carcinoma (BCC) with imiquimod also will be discussed...
Linezolid and quinupristin/dalfopristin: novel antibiotics for gram-positive infections of the skinEric S Schweiger
Department of Dermatology, St Luke s Roosevelt Hospital Center, Beth Israel Medical Center, New York, New York, USA
J Drugs Dermatol 2:378-83. 2003..Several new drugs have emerged as possible therapeutic alternatives. This review focuses on agents newly introduced and FDA-approved for the treatment of skin and skin structure infections: linezolid and quinupristin/dalfopristin...
Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agentsJeffrey M Sobell
Tufts Medical Center, Department of Dermatology, Boston, MA 02111, USA
J Drugs Dermatol 8:230-8. 2009..One of these new agents is ustekinumab, a humanized antibody that targets interleukins 12 and 23 and inhibits the differentiation of Th17 cells, a recently identified subset of CD4+ T-helper cells...
The preauricular sinus: a review of its clinical presentation, treatment, and associationsNoah S Scheinfeld
Department of Dermatology, St Luke s Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York, USA
Pediatr Dermatol 21:191-6. 2004..Recurrence rates after surgery range from 9% to 42%. Meticulous excision by an experienced head and neck surgeon minimizes the risk of recurrence...
Famciclovir for cutaneous herpesvirus infections: an update and review of new single-day dosing indicationsManju Chacko
Department of Dermatology, St Luke s Roosevelt Hospital Center, 1090 Amsterdam Ave, New York, NY 10025, USA
Cutis 80:77-81. 2007..Famciclovir has received single-day dosing indications for both of these entities. The studies leading to these new indications are reviewed...
Novel antibacterial agents for skin and skin structure infectionsEric S Schweiger
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025, USA
J Am Acad Dermatol 50:331-40; quiz 341-2. 2004....
Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 3: Clinical managementErin H Kil
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
Cutis 81:327-35. 2008..This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The third part of the review will focus on the clinical management of MRSA infection...
Linezolid, quinupristin/dalfopristin, and daptomycin in dermatologyKaren M Wesson
Department of Dermatology, St. Luke's-Roosevelt Center, New York, New York 10025, USA
Clin Dermatol 21:64-70. 2003
EfalizumabManju Chacko
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York 10025, USA
Dermatol Ther 20:265-9. 2007..In addition, several off-label applications of efalizumab will be reviewed...
Successful treatment of multiple superficial basal cell carcinomas with topical imiquimod: case report and review of the literatureMolly M Drehs
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA
Dermatol Surg 28:427-9. 2002..There was no clinical evidence of any recurrent tumor. CONCLUSION: Imiquimod 5% cream appears to be effective for multiple, superficial BCCs unresponsive to other modalities...
Therapeutic options for herpes labialis, I: Oral agentsDiana Elish
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
Cutis 74:31-4. 2004..In this series of articles, we review oral and topical therapeutic agents that are available in the treatment of herpes labialis and its associated symptoms. This article will review oral treatment options...
Viral skin infections in the elderly: diagnosis and managementRashmi Bansal
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, 1090 Amsterdam Avenue, New York, NY 10025, USA
Drugs Aging 19:503-14. 2002..Immunocompromised patients often do not respond to the usual destructive therapies, and intravenous or topical cidofovir may be useful in these patients...
Partial remission of psoriasis following rituximab therapy for non-Hodgkin lymphomaFiza Singh
Department of Dermatology, St Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
Cutis 76:186-8. 2005....
Successful treatment of severe atopic dermatitis in a child and an adult with the T-cell modulator efalizumabJeffrey M Weinberg
Department of Dermatology, St Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY, USA
Arch Dermatol 142:555-8. 2006
Comparison of diagnostic methods in the evaluation of onychomycosisJeffrey M Weinberg
Department of Dermatology at St Luke s Roosevelt Hospital Center, New York, NY 10025, USA
J Am Acad Dermatol 49:193-7. 2003..Recent reports have suggested that nail plate biopsy using periodic acid-Schiff (PAS) (Bx/PAS) stain may be a very sensitive technique for the diagnosis of onychomycosis...
Cutaneous anthrax: a concise reviewWilliam D Tutrone
Department of Dermatology, St. Luke's-Roosevelt Medical Center, New York, New York 10025, USA
Cutis 69:27-33. 2002....
Cutaneous HSV-2 infection with serial recurrences at multiple sitesAnne Dacko
Department of Dermatology, St. Luke's-Roosevelt/Beth Israel Medical Center, New York, NY 10025, USA
Int J Dermatol 41:109-11. 2002
Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 4: Additional therapeutic considerationsErin H Kil
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
Cutis 81:343-7. 2008..The fourth part of the review will focus on additional therapeutic considerations in the management of MRSA infection...
Utility of histopathologic analysis in the evaluation of onychomycosisJeffrey M Weinberg
Clinical Research Center, Department of Dermatology, St Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
J Am Podiatr Med Assoc 95:258-63. 2005..We propose that histopathologic examination is indicated if the results of other methods are negative and clinical suspicion is high; therefore, it is a useful complementary technique in the diagnosis of onychomycosis...
Oral tazarotene and oral pimecrolimus: novel oral therapies in development for psoriasisFiza Singh
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA
J Drugs Dermatol 3:141-3. 2004..The goal of this article is to review oral tazarotene, a novel retinoid, and oral pimecrolimus, a novel macrolactam therapy, for the treatment of moderate to severe psoriasis...
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitisRachel Nazarian
St Lukes Roosevelt Hospital Center, Department of Dermatology, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Curr Opin Investig Drugs 10:1236-42. 2009..AN-2728 appears to have good therapeutic potential, although further and larger trials are required to assess the long-term safety and characterize the broad utility of this drug...
Medical backgrounder: psoriasisLisa Travis
Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, New York, NY, U.S.A
Drugs Today (Barc) 38:847-65. 2002..New psoriasis treatment regimens have been developed and include combination, rotational and sequential therapy...
Management of moderate to severe plaque psoriasis (part I): clinical update on antitumor necrosis factor agentsJeffrey M Sobell
Tufts Medical Center, Department of Dermatology, Boston, Massachusetts SkinCare Physicians, Chestnut Hill, MA 02111, USA
J Drugs Dermatol 8:147-54. 2009..Part 2 will present new data on T-cell modulators, new molecules in development, and considerations for optimal therapeutic selection for treatment of patients with psoriasis (Journal of Drugs in Dermatology, March 2009)...
A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgiaKatherine Holcomb
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
J Drugs Dermatol 5:863-6. 2006..5% (P < .001), and reduced the incidence of herpes zoster by 51.3% (P < .001). In this review, we will discuss the history of the use of the varicella vaccine in children, and the subsequent development of the new zoster vaccine...
Neonatal pemphigus foliaceusRanella Hirsch
Department of Dermatology, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA
J Am Acad Dermatol 49:S187-9. 2003..The proposed mechanism of disease transfer is the passive transfer of maternal IgG antibodies across the placenta...
Successful treatment of vitiligo with 0.1% tacrolimus ointmentLisa B Travis
St Luke's-Roosevelt Hospital Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Arch Dermatol 139:571-4; discussion 573. 2003
Macrolides in dermatologyNoah S Scheinfeld
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA
Clin Dermatol 21:40-9. 2003
Topical antibacterial agents for wound care: a primerCandace Thornton Spann
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
Dermatol Surg 29:620-6. 2003..The ideal topical antibiotic has a broad spectrum of activity, has persistent antibacterial effects, and has minimal toxicity or incidence of allergy...
Monodermatomal herpes zoster in a pseudodisseminated distribution following breast reconstruction surgeryMicole Tuchman
New York Medical College, New York, USA
Cutis 81:71-2. 2008....
Topical antimicrobial agents in dermatologyCandace Thornton Spann
Department of Dermatology, St. Luke's-Roosevelt Center, New York, New York 10025, USA
Clin Dermatol 21:70-7. 2003
Idiopathic eruptive macular pigmentation: a case of 21 years' durationSheetal Mehta
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, NY 10025, USA
J Am Acad Dermatol 49:S280-2. 2003..An unusual case of a 24-year-old woman with idiopathic eruptive macular pigmentation lasting 21 years was characterized by several periods of spontaneous resolution followed by recurrences...
Lichen planus in the lines of BlaschkoChristina Kabbash
Department of Dermatology, St Luke's-Roosevelt Hospital Center, New York, New York 10025, USA
Pediatr Dermatol 19:541-5. 2002..Based on the clinical findings in our patients and a review of the English-language literature, we believe that linear LP is usually distributed along the lines of Blaschko and should be renamed lichen planus, Blaschko subtype...
Neurocutaneous disordersJoseph S Barbagallo
Department of Dermatology, St. Luke's-Roosevelt and Beth Israel Medical Centers, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Dermatol Clin 20:547-60, viii. 2002..Many of these diseases are single gene disorders, for which the genes have been discovered in the past few years. The article is divided into sections, highlighting disorders transmitted by different inheritance pattern...
Therapeutic options for herpes labialis, II: Topical agentsDiana Elish
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, New York, New York 10025, USA
Cutis 74:35-40. 2004
Study of clinically suspected onychomycosis in a podiatric populationMaureen B Jennings
New York College of Podiatric Medicine, 1800 Park Ave, New York, NY 10035, USA
J Am Podiatr Med Assoc 92:327-30. 2002..The most remarkable risk factor was age, with 80% of affected individuals older than 35 years. False-negatives may account for the high percentage (44%) of negative cultures in this study...
Phototherapy of atopic dermatitisNoah S Scheinfeld
Department of Dermatology, St. Luke's-Roosevelt Hospital Center, New York, New York 10025, USA
Clin Dermatol 21:241-8. 2003
The anti-inflammatory effects of tetracyclinesJeffrey M Weinberg
Clinical Research Center, Department of Dermatology, St Luke's-Roosevelt Hospital Center, New York, New York, USA
Cutis 75:6-11. 2005..In addition, the use of subantimicrobial dose doxycycline 20 mg twice a day (SDD) will be discussed because of its anti-inflammatory effects...
Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 2: Pathogenesis and cutaneous manifestationsErin H Kil
Department of Dermatology, St Lukes Roosevelt Hospital Center, New York, New York, USA
Cutis 81:247-54. 2008..This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The second part of the review will focus on the pathogenesis and cutaneous manifestations of MRSA infection...
Atypical cellular neurothekeomaSonal Bhatia
Department of Dermatology, St. Luke's-Roosevelt Hospital Center and Beth Israel Medical Center, 1090 Amsterdam Avenue, Suite 11D, New York, NY 10025, USA
Dermatol Surg 29:1154-7. 2003..Although the atypical features raise concern about the malignant potential of this lesion, previous cases show that complete surgical excision of these lesions is curative...
Methicillin-resistant Staphylococcus aureus: an update for the dermatologist, Part 1: EpidemiologyErin H Kil
Department of Dermatology, St Luke s Roosevelt Hospital Center, New York, New York, USA
Cutis 81:227-33. 2008..This 4-part review covers the epidemiology, pathogenesis, and management of the disease, including new treatment options. The first part of the review will focus on the epidemiology of MRSA infection...
Topical imiquimod 5% cream in the treatment of Bowen's disease of the penisFran Cook-Bolden
J Am Acad Dermatol 46:146-7. 2002
Novel biologic therapiesJeffrey M Weinberg
Rev Recent Clin Trials 1:183. 2006
Successful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplanted patientLisa B Travis
Acta Derm Venereol 82:475-6. 2002
Topical therapy for actinic keratoses, I: 5-Fluorouracil and imiquimodWilliam D Tutrone
University of Vermont, Burlington, USA
Cutis 71:365-70. 2003..Therapies include 5-fluorouracil, imiquimod, diclofenac, colchicine, and retinoids. The first part of this review will focus on topical 5-fluorouracil and imiquimod...
Topical therapy for actinic keratoses, II: Diclofenac, colchicine, and retinoidsWilliam D Tutrone
University of Vermont, Burlington, USA
Cutis 71:373-9. 2003..This article is the second in a 2-part series of current topical therapeutic options for AKs and discusses topical diclofenac, colchicine, and retinoids. The first part focused on topical 5-fluorouracil and imiquimod...
Linezolid, quinupristin/dalfopristin, and daptomycin in dermatologyKaren M Wesson
Dis Mon 50:395-406. 2004
Unique approaches for the topical treatment and prevention of cutaneous infections: report from a clinical roundtableLawrence F Eichenfield
Division of Dermatology, University of California, San Diego School of Medicine, USA
Cutis 74:2-23. 2004
Barriers to biologicsJeffrey M Weinberg
Cutis 74:164. 2004
Learning curveJeffrey M Weinberg
Cutis 72:349. 2003
Psoriasis in the patient with human immunodeficiency virus, part 1: review of pathogenesisRita V Patel
University of Miami School of Medicine, Florida, USA
Cutis 82:117-22. 2008..The first part of the series focuses on the pathogenesis of HIV-associated psoriasis...
Pimple positivesJeffrey M Weinberg
Cutis 76:96. 2005
Perspectives on psoriasisJeffrey M Weinberg
Cutis 76:171. 2005
Nature of the beastJeffrey M Weinberg
Cutis 71:343. 2003
UV dependenceJeffrey M Weinberg
Cutis 78:25-6. 2006
